AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease.
PRIVATEAug 05, 2026•about 2 months ago
Amount Raised
$46 Million
Round Type
Series B
GlasgowBiotechnology
Investors
RocheScottish National Investment Bank
Description
Mironid, a biopharmaceutical company, has raised $46 million in a Series B funding round. The investment will support the clinical development of its treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). With funding from the Scottish National Investment Bank and Roche, the company aims to transform treatment for patients. This financing validates their approach in treating rare kidney diseases.
Company Information
Company
Mironid
Location
Glasgow, Kentucky, United States
About
Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.
Fundz sees it the moment Mironid raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
GlasgowBiotechnology